Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Status:
Not yet recruiting
Trial end date:
2025-11-04
Target enrollment:
Participant gender:
Summary
This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC)
that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is
the second leading cause of cancer-related deaths in the world. Liver transplantation is a
potentially curative treatment option for HCC, however, up to 20% of patients develop
recurrent disease after liver transplantation and prognosis remains poor. Lenvatinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Systemic
treatments for HCC have not been studied in patients with recurrent HCC after liver
transplantation, so there is no established therapy for these patients. This phase II trial
evaluates lenvatinib for this purpose.